These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11720854)

  • 1. Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
    Liu KG; Lambert MH; Ayscue AH; Henke BR; Leesnitzer LM; Oliver WR; Plunket KD; Xu HE; Sternbach DD; Willson TM
    Bioorg Med Chem Lett; 2001 Dec; 11(24):3111-3. PubMed ID: 11720854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
    J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
    Collins JL; Blanchard SG; Boswell GE; Charifson PS; Cobb JE; Henke BR; Hull-Ryde EA; Kazmierski WM; Lake DH; Leesnitzer LM; Lehmann J; Lenhard JM; Orband-Miller LA; Gray-Nunez Y; Parks DJ; Plunkett KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5037-54. PubMed ID: 9836621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
    Brooks DA; Etgen GJ; Rito CJ; Shuker AJ; Dominianni SJ; Warshawsky AM; Ardecky R; Paterniti JR; Tyhonas J; Karanewsky DS; Kauffman RF; Broderick CL; Oldham BA; Montrose-Rafizadeh C; Winneroski LL; Faul MM; McCarthy JR
    J Med Chem; 2001 Jun; 44(13):2061-4. PubMed ID: 11405642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
    Koyama H; Boueres JK; Han W; Metzger EJ; Bergman JP; Gratale DF; Miller DJ; Tolman RL; MacNaul KL; Berger JP; Doebber TW; Leung K; Moller DE; Heck JV; Sahoo SP
    Bioorg Med Chem Lett; 2003 May; 13(10):1801-4. PubMed ID: 12729668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
    Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR
    J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylacetic acid derivatives as hPPAR agonists.
    Santini C; Berger GD; Han W; Mosley R; MacNaul K; Berger J; Doebber T; Wu M; Moller DE; Tolman RL; Sahoo SP
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1277-80. PubMed ID: 12657263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
    Henke BR
    J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
    Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
    Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.
    Desai RC; Han W; Metzger EJ; Bergman JP; Gratale DF; MacNaul KL; Berger JP; Doebber TW; Leung K; Moller DE; Heck JV; Sahoo SP
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2795-8. PubMed ID: 12873517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
    Sauerberg P; Pettersson I; Jeppesen L; Bury PS; Mogensen JP; Wassermann K; Brand CL; Sturis J; Wöldike HF; Fleckner J; Andersen AS; Mortensen SB; Svensson LA; Rasmussen HB; Lehmann SV; Polivka Z; Sindelar K; Panajotova V; Ynddal L; Wulff EM
    J Med Chem; 2002 Feb; 45(4):789-804. PubMed ID: 11831892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists.
    Desai RC; Gratale DF; Han W; Koyama H; Metzger E; Lombardo VK; MacNaul KL; Doebber TW; Berger JP; Leung K; Franklin R; Moller DE; Heck JV; Sahoo SP
    Bioorg Med Chem Lett; 2003 Oct; 13(20):3541-4. PubMed ID: 14505666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
    Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
    Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
    Reddy KA; Lohray BB; Bhushan V; Reddy AS; Rao Mamidi NV; Reddy PP; Saibaba V; Reddy NJ; Suryaprakash A; Misra P; Vikramadithyan RK; Rajagopalan R
    J Med Chem; 1999 Aug; 42(17):3265-78. PubMed ID: 10464013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia.
    Lagu B; Pio B; Lebedev R; Yang M; Pelton PD
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3497-503. PubMed ID: 17485209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes.
    Moller DE; Greene DA
    Adv Protein Chem; 2001; 56():181-212. PubMed ID: 11329854
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
    Ibrahim MK; Eissa IH; Alesawy MS; Metwaly AM; Radwan MM; ElSohly MA
    Bioorg Med Chem; 2017 Sep; 25(17):4723-4744. PubMed ID: 28720328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.
    Jiang G; Dallas-Yang Q; Biswas S; Li Z; Zhang BB
    Biochem J; 2004 Jan; 377(Pt 2):339-46. PubMed ID: 14556646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.